AKT1 and head and neck squamous cell carcinoma: Recently, the use of Src inhibitor dasatinib for treating OSCC has been proposed as an attractive strategy via inhibiting Src downstream signaling pathway PI3K/Akt/mTOR and MEK/ERK in HNSCC [75].